Roivant’s Lisraya Succeeds in Phase 3 Eye Disease Trials
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Roivant and Priovant said Lisraya outperformed placebo against non-infectious uveitis in two Phase 3 trials involving 371 patients. Roivant plans to seek approval in the first half of 2027, expanding beyond the drug’s approved use for dermatomyositis.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu